23145-19-9

Basic information

• Product Name: 5-Methoxybenzofuran-2-carbaldehyde
• Synonyms: 5-Methoxy-2-benzofurancarbaldehyde;5-Methoxybenzofuran-2-carbaldehyde;5-methoxy-1-benzofuran-2-carbaldehyde
• CAS NO: 23145-19-9
• Molecular Formula: C₁₀H₈O₃
• Molecular Weight: 176.17
• Mol File: 23145-19-9.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 296 °C at 760 mmHg
• Flash Point: 132.8 °C
• Appearance: /
• Density: 1.24 g/cm³
• Vapor Pressure: 0.00147mmHg at 25°C
• Refractive Index: 1.619
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Methoxybenzofuran-2-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methoxybenzofuran-2-carbaldehyde(23145-19-9)
• EPA Substance Registry System: 5-Methoxybenzofuran-2-carbaldehyde(23145-19-9)

Safety Data

• Hazardous Substances Data: 23145-19-9(Hazardous Substances Data)

Usage

General Description

5-Methoxybenzofuran-2-carbaldehyde is a chemical compound with the molecular formula C10H8O3. It is a benzofuran derivative and aldehyde, containing a methoxy group at the 5-position and an aldehyde functional group at the 2-position on the benzene ring. 5-Methoxybenzofuran-2-carbaldehyde is used in the synthesis of various organic compounds and is also of interest in the field of medicinal chemistry due to its potential pharmacological properties. Its unique structure and reactivity make it a valuable building block for the creation of diverse chemical structures in pharmaceutical research and development.

InChI:InChI=1/C10H8O3/c1-12-8-2-3-10-7(4-8)5-9(6-11)13-10/h2-6H,1H3

Upstream product

• 23145-29-1 2-(2,2-Dimethoxy-ethoxy)-5-methoxy-benzaldehyde 
• 37603-26-2 2-(hydroxymethyl)-5-methoxy-benzo[b]furan 
• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 10242-08-7 5-methoxybenzofuran-2-carboxylic acid 
• 1254062-17-3 (2-formyl-4-methoxyphenoxy)acetaldehyde diethyl acetal 
• 50551-56-9 ethyl 5-methoxybenzofuran-2-carboxylate 
• 150-76-5 4-methoxy-phenol 

Downstream Products

• 139201-62-0 2-<2-(4-chlorophenyl)ethenyl>-5-methoxybenzofuran 
• 107092-74-0 5-Methoxy-2-[(Z)-2-nitro-3-(3,4,5-trimethoxy-phenyl)-propenyl]-benzofuran 
• 622863-29-0 5-methoxy-2-[(E,Z)-2-phenylethenyl]-1-benzofuran 
• 622863-31-4 5-methoxy-2-[(E,Z)-2-(2-chlorophenyl)ethenyl]-1-benzofuran 
• 622863-30-3 9-methoxy-4-phenyl-1H-[1]benzofuro[3,2-e]isoindole-1,3(2H)-dione 
• 622863-32-5 4-(2-chlorophenyl)-9-methoxy-1H-[1]benzofuro[3,2-e]isoindole-1,3(2H)-dione 
• 139201-63-1 2-<2-(4-chlorophenyl)ethenyl>-5-benzofuranol 
• 138853-86-8 2-<2-(4-chlorophenyl)ethyl>-2,3-dihydro-5-benzofuranol 
• 138853-90-4 2-<2-(4-chlorophenyl)ethyl>-2,3-dihydro-6-(3-phenoxypropyl)-5-benzofuranol 
• 1429509-57-8 (E)-5-methoxy-2-(4-methylstyryl)benzofuran 
• 1429509-14-7 (Z)-5-methoxy-2-(4-methylstyryl)benzofuran 

Relevant articles and documents

alpha-SYNUCLEIN AGGREGATE BINDING AGENT AND IMAGING METHOD

The present invention provides an α-synuclein aggregate binding agent that has high binding selectivity for an α-synuclein aggregate. The α-synuclein aggregate binding agent contains a compound represented by a formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: in the formula (I), R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; the ring A is a benzene or pyridine ring; the ring B is represented by the following formula (i) or (ii): R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl.

Synthesis, anti-inflammatory evaluation in vivo and docking studies of some new 5-(benzo[b]furan-2-ylmethyl)-6-methyl-pyridazin-3(2H)-one derivatives

Seven novel 5-(benzo[b]furan-2-ylmethyl)-6-methyl-pyridazin-3(2H)-one derivatives (6a to 6g) have been synthesized by the condensation of appropriate 3-(benzofuran-2-ylmethylene)-4-oxopentanoic acid and hydrazine hydrate in ethanol. Structures of all compounds were elucidated by elemental analysis, IR, 1H NMR and 13C NMR. These compounds were tested for their anti-inflammatory activity in carrageenan-induced rat paw edema model. In silico molecular docking study has been executed to study the binding interactions of the synthesized compounds with COX-2 protein. Compounds 6a, 6b, 6e and 6g showed a good anti-inflammatory activity at 50 mg/kg compared with the indometacin at 10 mg/kg and the aspirin at 150 mg/kg and good binding affinity with COX-2.

TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS

The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.